Trial · NCT07886944

PATH to Reducing Burnout Among Peers Who Deliver Overdose Prevention Services (R33 Phase Clinical Trial)

NCT07886944, Not applicable, Enrolling by invitation, Chestnut Health Systems

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. PATH to Reducing Burnout Among Peers Who Deliver Overdose Prevention Services (R33 Phase Clinical Trial). Trials, record NCT07886944. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886944

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: PATH to Reducing Burnout Among Peers Who Deliver Overdose Prevention Services (R33 Phase Clinical Trial)
NCT number: NCT07886944
Status: Enrolling by invitation
Phases: Not applicable
Enrollment: 200 participants, estimated
Lead sponsor: Chestnut Health Systems
Conditions: Burnout, Secondary Trauma, Compassion Fatigue, Opioid Use Disorder, Stimulant Use Disorder, Substance Use Disorder
Interventions: PATH (Peer Advanced Training for total Health)
First posted: 2026-10-21
Last updated: 2026-10-27

Source ClinicalTrials.gov

Registered outcomes18

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Job Approach Crafting	Every 4 months from enrollment to 29 months post-enrollment.	Measured using the Adaptive Adjustment Job Crafting Scale (AAJCS), a validated instrument using a 7-point Likert scale (1/Totally disagree -7/Totally agree) measuring participants' proactive cognitive strategies for adapting to work demands and resources. This sub-scale is scored by averaging responses and has a minimum score of 1 and a maximum score of 7. Higher scores reflect greater utilization of job crafting approaches.
Secondary	Job Avoidance Crafting	Every 4 months from enrollment to 29 months post-enrollment.	Measured using the Adaptive Adjustment Job Crafting Scale (AAJCS), a validated instrument using a 7-point Likert scale (1/Totally disagree -7/Totally agree) measuring participants' proactive cognitive strategies for adapting to work demands and resources. This sub-scale is scored by averaging responses and has a minimum score of 1 and a maximum score of 7. Higher scores reflect greater utilization of job crafting approaches.
Secondary	Professional Quality of Life	Every 4 months from enrollment to 29 months post-enrollment.	Measured using the 30-item Professional Quality of Life instrument, which assesses positive and negative aspects of helping professionals' work experiences. Respondents are asked to rate how often they have experienced items over the past 30 days on a 5-point Likert scale (1/Never-5/Very often). The measure includes 3 sub-scales: Compassion Satisfaction (10 items), Burnout (10 items), and Secondary Traumatic Stress (10 items). Each has a minimum score of 10 and a maximum of 50. Higher scores of Compassion Satisfaction reflect greater satisfaction related to one's ability to be an effective caregiver. Higher scores of Burnout reflect greater risk of burnout associated with difficulties in dealing with work. Higher scores of Secondary Traumatic Stress reflect higher exposure to traumatically stressful events.
Secondary	Overdose Prevention Knowledge, Attitudes, and Skills	Every 4 months from enrollment to 29 months post-enrollment.	Measured using the Harm Reduction Knowledge, Attitudes, and Skills (HR-KAS), a 20-item scale assessing conceptual understanding and application of overdose prevention in peer recovery work. Participants are asked to rate each item on a 10-point Likert scale. Subscales of the HR-KAS include: Knowledge (5 items; 1/no knowledge-10/high level of knowledge), Attitudes (6 items; 1/strongly disagree-10/strongly agree), and Skills (9 items; 1/cannot do at all-10/highly certain). Each sub-scale is scored by averaging responses and has a minimum score of 1 and a maximum score of 10. Higher scores indicate higher perceptions of overdose prevention knowledge, agreement with overdose prevention efforts, and confidence with delivering overdose prevention services.
Secondary	Overdose Prevention Recovery Plan Integration	From enrollment to 29 months post-enrollment	This is the extent to which individual overdose prevention strategies are included in client recovery plans. This will be measured by reviewing client recovery plans and identifying the number of overdose prevention approaches incorporated in each plan, which requires peer understanding of clients' individualized needs as it relates to substance use and community supervision terms. This measure will be calculated by reviewing and qualitatively coding all instances of overdose prevention within recovery plan documents and then averaging across all documents at each time point by staff person and site.
Secondary	Client Retention	From enrollment to 29 months post-enrollment	Measured taking the total number of clients served by the program for a minimum of 30 days within the month and dividing it by the total number of clients served in that month. Measured using RCO-level administrative data.
Other	Staff Boundaries with Clients	Every 4 months from enrollment to 29 months post-enrollment.	Measured using 7 original items with a 7-point Likert scale (1/Strongly disagree - 7/Strongly agree) assessing participants ability to maintain healthy work-related boundaries with clients. The instrument is scored by averaging responses and has a minimum score of 1 and a maximum score of 7. A lower score reflects greater boundary management.
Other	Moral Injury	Every 4 months from enrollment to 29 months post-enrollment.	Measured using 6 unmodified items and 1 modified item from the Moral Injury Symptoms Scale-Health Professional (MISS-HP) which assesses distress resulting from workplace situations that conflict with personal or professional values using a 10-point Likert scale (1/Strongly disagree - 10/Strongly agree). The instrument has a minimum score of 7 and a maximum of 70. A higher score reflects greater internal moral conflict, guilt or shame, spiritual struggle, loss of meaning, difficulty forgiving oneself, or difficulty with strength of personal recovery.
Other	Bias Against Overdose Prevention	Every 4 months from enrollment to 29 months post-enrollment.	Measured using the Harm Reduction Stigma Scale, a 24-item instrument assessing stigmatizing attitudes toward overdose prevention and people who use drugs using a 3-point Likert scale (1/Agree - 3/Disagree). The instrument is scored by averaging responses and has a minimum score of 1 and a maximum score of 3. A lower score reflects fewer stigmatizing attitudes.
Other	Training Satisfaction	Immediately post-completion of PATH eLearning and PATH ECHO	Measured using the Training Satisfaction Questionnaire, a custom 5-point Likert-scale (1/Totally disagree - 5/Totally agree) survey with 12-items assessing overall satisfaction with the learning experience, content relevance, and applicability to peer support practice. The questionnaire includes 3 sub-scales: Objectives and Content (3 items), Methods and Training Context (6 items), and Usefulness and Overall Rating (3 items). Each sub-scale is scored by averaging responses and has a minimum score of 1 and a maximum score of 5. Higher scores indicate higher levels of satisfaction with the training.

1 to 10 of 18Source ClinicalTrials.gov

See all 18 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R33DA061340

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07886944

GET https://conductscience.org/api/trials/v1/NCT07886944/registered

API reference For AI assistants